Sunday, July 12, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 341
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

341 results for “Novartis” Back to intelligence hub

Search results

Page 11 of 15
  1. LCZ696

    Novartis Pharmaceuticals

    Hypertension

    phase 2 small molecule completed

    2 trials
  2. LDE225 0.75%

    Novartis Pharmaceuticals

    Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

    phase 2 small molecule terminated

    1 trial
  3. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial
  4. LNA043

    Novartis Pharmaceuticals

    Osteoarthritis

    phase 2 small molecule active

    1 trial
  5. MAS825, -

    Novartis Pharmaceuticals

    Still’s disease

    phase 2 small molecule active

    1 trial
  6. Midostaurin

    Novartis Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial
  7. Nilotinib followed by treatment-free

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial
  8. Osilodrostat

    Novartis Pharmaceuticals

    Cushing's Syndrome

    phase 2 small molecule completed

    1 trial
  9. PHE885

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 2 mab terminated

    1 trial
  10. PPY988A

    Novartis Pharmaceuticals

    Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the previous studies GT005-01 (FOCUS), GT005-02 (EXPLORE) and GT005-03 (HORIZON).

    phase 2 small molecule active

    1 trial
  11. Panobinostat

    Novartis Pharmaceuticals

    Classical Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial
  12. Patupilone

    Novartis Pharmaceuticals

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial
  13. QBW251

    Novartis Pharmaceuticals

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial
  14. Rapcabtagene autoleucel

    Novartis Pharmaceuticals

    ANCA Associated Vasculitis (AAV)

    phase 2 mab active

    1 trial
  15. SODIUM CHLORIDE , DII235

    Novartis Pharmaceuticals

    Cardiovascular risk reduction in participants with elevated Lp(a)

    phase 2 small molecule active

    1 trial
  16. Scemblix 40 mg film-coated tablets

    Novartis Pharmaceuticals

    CML-CP or CML-AP patients with T315I mutation

    phase 2 small molecule active

    1 trial
  17. Seasonal flu vaccine

    Novartis Pharmaceuticals

    Seasonal Influenza

    phase 2 mab completed

    1 trial
  18. Serelaxin

    Novartis Pharmaceuticals

    Acute Heart Failure

    phase 2 small molecule completed

    1 trial
  19. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial
  20. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    Adult patients with refractory or relapsed follicular lymphoma

    phase 2 small molecule active

    1 trial
  21. Vi-CRM197 vaccine

    Novartis Pharmaceuticals

    Typhoid Fever

    phase 2 mab completed

    1 trial
  22. alb-interferon alfa 2b

    Novartis Pharmaceuticals

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial
  23. cyclosporine (reduced exposure) / everolimus

    Novartis Pharmaceuticals

    Kidney Transplantation

    phase 2 small molecule completed

    1 trial
  24. eltrombopag

    Novartis Pharmaceuticals

    Thrombocytopaenia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.